Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Gattei

Showing results (141-150 of 190) with videos related to

Pageof 19
Sort By:
Blood|February 7, 2012
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemiaDavide Rossi, Marco Fangazio, Silvia Rasi, et al.
Cancers|April 12, 2022
5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 PathwayFederica Tonon, Maja Cemazar, Urska Kamensek, et al.
Blood|November 1, 2011
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessDavide Rossi, Alessio Bruscaggin, Valeria Spina, et al.
Cancers|March 28, 2026
Correction: Tonon et al. 5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway. <i>Cancers</i> 2022, <i>14</i>, 1630Federica Tonon, Maja Cemazar, Urska Kamensek, et al.
Blood|December 18, 2012
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaDavide Rossi, Silvia Rasi, Valeria Spina, et al.
British Journal of Haematology|November 28, 2008
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre studyRiccardo Bomben, Michele Dal Bo, Daniela Capello, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Blood|December 7, 2006
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter studyRiccardo Bomben, Michele Dal Bo, Daniela Capello, et al.
Blood|May 3, 2013
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemiaDavide Rossi, Valeria Spina, Riccardo Bomben, et al.
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
Pageof 19

Showing results (141-150 of 190) with videos related to

Sort By:
Pageof 19
Blood|February 7, 2012
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemiaDavide Rossi, Marco Fangazio, Silvia Rasi, et al.
Cancers|April 12, 2022
5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 PathwayFederica Tonon, Maja Cemazar, Urska Kamensek, et al.
Blood|November 1, 2011
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessDavide Rossi, Alessio Bruscaggin, Valeria Spina, et al.
Cancers|March 28, 2026
Correction: Tonon et al. 5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway. <i>Cancers</i> 2022, <i>14</i>, 1630Federica Tonon, Maja Cemazar, Urska Kamensek, et al.
Blood|December 18, 2012
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaDavide Rossi, Silvia Rasi, Valeria Spina, et al.
British Journal of Haematology|November 28, 2008
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre studyRiccardo Bomben, Michele Dal Bo, Daniela Capello, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Blood|December 7, 2006
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter studyRiccardo Bomben, Michele Dal Bo, Daniela Capello, et al.
Blood|May 3, 2013
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemiaDavide Rossi, Valeria Spina, Riccardo Bomben, et al.
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
Pageof 19